Point  ||| S:0 E:6 ||| NN
prevalence  ||| S:6 E:17 ||| NN
survey  ||| S:17 E:24 ||| NN
of  ||| S:24 E:27 ||| IN
antimicrobial  ||| S:27 E:41 ||| JJ
use  ||| S:41 E:45 ||| NN
in  ||| S:45 E:48 ||| IN
Chinese  ||| S:48 E:56 ||| JJ
hospitals  ||| S:56 E:66 ||| NNS
in  ||| S:66 E:69 ||| IN
2012  ||| S:69 E:74 ||| CD
In  ||| S:74 E:77 ||| IN
China ||| S:77 E:82 ||| NNP
,  ||| S:82 E:84 ||| ,
several  ||| S:84 E:92 ||| JJ
measures  ||| S:92 E:101 ||| NNS
have  ||| S:101 E:106 ||| VBP
been  ||| S:106 E:111 ||| VBN
adopted  ||| S:111 E:119 ||| VBN
to  ||| S:119 E:122 ||| TO
decrease  ||| S:122 E:131 ||| VB
unnecessary  ||| S:131 E:143 ||| JJ
antimicrobial  ||| S:143 E:157 ||| JJ
overuse  ||| S:157 E:165 ||| NN
since  ||| S:165 E:171 ||| IN
2010 ||| S:171 E:175 ||| CD
.  ||| S:175 E:177 ||| .
This  ||| S:177 E:182 ||| DT
study  ||| S:182 E:188 ||| NN
aimed  ||| S:188 E:194 ||| VBN
to  ||| S:194 E:197 ||| TO
identify  ||| S:197 E:206 ||| VB
characteristics  ||| S:206 E:222 ||| NNS
of  ||| S:222 E:225 ||| IN
antimicrobial  ||| S:225 E:239 ||| JJ
use  ||| S:239 E:243 ||| NN
in  ||| S:243 E:246 ||| IN
Chinese  ||| S:246 E:254 ||| JJ
hospitals  ||| S:254 E:264 ||| NNS
after  ||| S:264 E:270 ||| IN
implementing  ||| S:270 E:283 ||| VBG
these  ||| S:283 E:289 ||| DT
measures  ||| S:289 E:298 ||| NNS
and  ||| S:298 E:302 ||| CC
to  ||| S:302 E:305 ||| TO
explore  ||| S:305 E:313 ||| VB
additional  ||| S:313 E:324 ||| JJ
targets  ||| S:324 E:332 ||| NNS
for  ||| S:332 E:336 ||| IN
future  ||| S:336 E:343 ||| JJ
antimicrobial  ||| S:343 E:357 ||| JJ
stewardship ||| S:357 E:368 ||| NN
.  ||| S:368 E:370 ||| .
In  ||| S:370 E:373 ||| IN
2012 ||| S:373 E:377 ||| CD
,  ||| S:377 E:379 ||| ,
point  ||| S:379 E:385 ||| NN
prevalence  ||| S:385 E:396 ||| NN
surveys  ||| S:396 E:404 ||| NNS
conducted  ||| S:404 E:414 ||| VBN
in  ||| S:414 E:417 ||| IN
Chinese  ||| S:417 E:425 ||| JJ
hospitals  ||| S:425 E:435 ||| NNS
included  ||| S:435 E:444 ||| VBD
inpatients  ||| S:444 E:455 ||| NNS
who  ||| S:455 E:459 ||| WP
were  ||| S:459 E:464 ||| VBD
admitted  ||| S:464 E:473 ||| VBN
for  ||| S:473 E:477 ||| IN
at  ||| S:477 E:480 ||| IN
least  ||| S:480 E:486 ||| JJS
24  ||| S:486 E:489 ||| CD
hours ||| S:489 E:494 ||| NNS
.  ||| S:494 E:496 ||| .
Details  ||| S:496 E:504 ||| NNS
regarding  ||| S:504 E:514 ||| VBG
infection ||| S:514 E:523 ||| NN
,  ||| S:523 E:525 ||| ,
antimicrobial  ||| S:525 E:539 ||| JJ
use ||| S:539 E:542 ||| NN
,  ||| S:542 E:544 ||| ,
and  ||| S:544 E:548 ||| CC
bacterial  ||| S:548 E:558 ||| JJ
cultures  ||| S:558 E:567 ||| NNS
were  ||| S:567 E:572 ||| VBD
recorded ||| S:572 E:580 ||| VBN
.  ||| S:580 E:582 ||| .
A  ||| S:582 E:584 ||| DT
survey  ||| S:584 E:591 ||| NN
of  ||| S:591 E:594 ||| IN
786,028  ||| S:594 E:602 ||| CD
inpatients  ||| S:602 E:613 ||| NN
in  ||| S:613 E:616 ||| IN
1,313  ||| S:616 E:622 ||| CD
hospitals  ||| S:622 E:632 ||| NNS
included  ||| S:632 E:641 ||| VBD
prevalence  ||| S:641 E:652 ||| VBN
of  ||| S:652 E:655 ||| IN
health  ||| S:655 E:662 ||| NN
care-associated  ||| S:662 E:678 ||| NNS
( ||| S:678 E:679 ||| -LRB-
3.22 ||| S:679 E:683 ||| CD
% ||| S:683 E:684 ||| NN
)  ||| S:684 E:686 ||| -RRB-
and  ||| S:686 E:690 ||| CC
community-acquired  ||| S:690 E:709 ||| JJ
infections  ||| S:709 E:720 ||| NNS
( ||| S:720 E:721 ||| -LRB-
22.52 ||| S:721 E:726 ||| NNP
% ||| S:726 E:727 ||| NN
) ||| S:727 E:728 ||| -RRB-
;  ||| S:728 E:730 ||| :
antimicrobial  ||| S:730 E:744 ||| JJ
use  ||| S:744 E:748 ||| NN
prevalence  ||| S:748 E:759 ||| NNS
( ||| S:759 E:760 ||| -LRB-
AUP ||| S:760 E:763 ||| NNP
,  ||| S:763 E:765 ||| ,
38.39 ||| S:765 E:770 ||| CD
% ||| S:770 E:771 ||| NN
) ||| S:771 E:772 ||| -RRB-
;  ||| S:772 E:774 ||| :
bacterial  ||| S:774 E:784 ||| JJ
culture  ||| S:784 E:792 ||| NN
rate  ||| S:792 E:797 ||| NN
( ||| S:797 E:798 ||| -LRB-
BCR ||| S:798 E:801 ||| NNP
,  ||| S:801 E:803 ||| ,
40.16 ||| S:803 E:808 ||| CD
% ||| S:808 E:809 ||| NN
) ||| S:809 E:810 ||| -RRB-
;  ||| S:810 E:812 ||| :
and  ||| S:812 E:816 ||| CC
proportions  ||| S:816 E:828 ||| NNS
of  ||| S:828 E:831 ||| IN
administration  ||| S:831 E:846 ||| NN
of  ||| S:846 E:849 ||| IN
a  ||| S:849 E:851 ||| DT
single  ||| S:851 E:858 ||| JJ
antimicrobial  ||| S:858 E:872 ||| NNS
( ||| S:872 E:873 ||| -LRB-
75.33 ||| S:873 E:878 ||| NNP
% ||| S:878 E:879 ||| NN
) ||| S:879 E:880 ||| -RRB-
,  ||| S:880 E:882 ||| ,
therapeutic  ||| S:882 E:894 ||| JJ
( ||| S:894 E:895 ||| -LRB-
23.16 ||| S:895 E:900 ||| NNP
% ||| S:900 E:901 ||| NN
) ||| S:901 E:902 ||| -RRB-
,  ||| S:902 E:904 ||| ,
prophylactic  ||| S:904 E:917 ||| NNS
( ||| S:917 E:918 ||| -LRB-
11.99 ||| S:918 E:923 ||| NNP
% ||| S:923 E:924 ||| NN
) ||| S:924 E:925 ||| -RRB-
,  ||| S:925 E:927 ||| ,
and  ||| S:927 E:931 ||| CC
therapeutic  ||| S:931 E:943 ||| CD
plus  ||| S:943 E:948 ||| CD
prophylactic  ||| S:948 E:961 ||| NNS
( ||| S:961 E:962 ||| -LRB-
3.24 ||| S:962 E:966 ||| NNP
% ||| S:966 E:967 ||| NN
)  ||| S:967 E:969 ||| -RRB-
AUP  ||| S:969 E:973 ||| NNP
rates ||| S:973 E:978 ||| NNS
.  ||| S:978 E:980 ||| .
Prophylactic  ||| S:980 E:993 ||| NNP
AUP  ||| S:993 E:997 ||| NNP
rates  ||| S:997 E:1003 ||| NNS
of  ||| S:1003 E:1006 ||| IN
hospitals  ||| S:1006 E:1016 ||| NNS
with  ||| S:1016 E:1021 ||| IN
< ||| S:1021 E:1022 ||| SYM
300 ||| S:1022 E:1025 ||| CD
,  ||| S:1025 E:1027 ||| ,
300-599 ||| S:1027 E:1034 ||| NNP
,  ||| S:1034 E:1036 ||| ,
600-899 ||| S:1036 E:1043 ||| NNP
,  ||| S:1043 E:1045 ||| ,
and  ||| S:1045 E:1049 ||| CC
≥900  ||| S:1049 E:1054 ||| CD
beds  ||| S:1054 E:1059 ||| NNS
were  ||| S:1059 E:1064 ||| VBD
14.23 ||| S:1064 E:1069 ||| CD
% ||| S:1069 E:1070 ||| NN
,  ||| S:1070 E:1072 ||| ,
12.45 ||| S:1072 E:1077 ||| CD
% ||| S:1077 E:1078 ||| NN
,  ||| S:1078 E:1080 ||| ,
11.45 ||| S:1080 E:1085 ||| CD
% ||| S:1085 E:1086 ||| NN
,  ||| S:1086 E:1088 ||| ,
and  ||| S:1088 E:1092 ||| CC
11.34 ||| S:1092 E:1097 ||| CD
% ||| S:1097 E:1098 ||| NN
,  ||| S:1098 E:1100 ||| ,
respectively ||| S:1100 E:1112 ||| RB
.  ||| S:1112 E:1114 ||| .
However ||| S:1114 E:1121 ||| RB
,  ||| S:1121 E:1123 ||| ,
BCRs  ||| S:1123 E:1128 ||| NNP
increased  ||| S:1128 E:1138 ||| VBD
with  ||| S:1138 E:1143 ||| IN
increasing  ||| S:1143 E:1154 ||| VBG
hospital  ||| S:1154 E:1163 ||| NN
bed  ||| S:1163 E:1167 ||| NN
numbers ||| S:1167 E:1174 ||| NNS
.  ||| S:1174 E:1176 ||| .
AUP  ||| S:1176 E:1180 ||| NNP
rates  ||| S:1180 E:1186 ||| NNS
for  ||| S:1186 E:1190 ||| IN
surgical  ||| S:1190 E:1199 ||| JJ
patients  ||| S:1199 E:1208 ||| NNS
with  ||| S:1208 E:1213 ||| IN
classes  ||| S:1213 E:1221 ||| NNS
I ||| S:1221 E:1222 ||| PRP
,  ||| S:1222 E:1224 ||| ,
II ||| S:1224 E:1226 ||| NNP
,  ||| S:1226 E:1228 ||| ,
and  ||| S:1228 E:1232 ||| CC
III  ||| S:1232 E:1236 ||| NNP
wounds  ||| S:1236 E:1243 ||| NNS
were  ||| S:1243 E:1248 ||| VBD
45.19 ||| S:1248 E:1253 ||| CD
% ||| S:1253 E:1254 ||| NN
,  ||| S:1254 E:1256 ||| ,
68.18 ||| S:1256 E:1261 ||| CD
% ||| S:1261 E:1262 ||| NN
,  ||| S:1262 E:1264 ||| ,
and  ||| S:1264 E:1268 ||| CC
68.47 ||| S:1268 E:1273 ||| CD
% ||| S:1273 E:1274 ||| NN
,  ||| S:1274 E:1276 ||| ,
respectively ||| S:1276 E:1288 ||| RB
.  ||| S:1288 E:1290 ||| .
Prophylactic  ||| S:1290 E:1303 ||| NNP
AUP  ||| S:1303 E:1307 ||| NNP
rates  ||| S:1307 E:1313 ||| NNS
for  ||| S:1313 E:1317 ||| IN
surgical  ||| S:1317 E:1326 ||| JJ
patients  ||| S:1326 E:1335 ||| NNS
decreased  ||| S:1335 E:1345 ||| VBD
with  ||| S:1345 E:1350 ||| IN
increasing  ||| S:1350 E:1361 ||| VBG
hospital  ||| S:1361 E:1370 ||| NN
bed  ||| S:1370 E:1374 ||| NN
numbers ||| S:1374 E:1381 ||| NNS
.  ||| S:1381 E:1383 ||| .
These  ||| S:1383 E:1389 ||| DT
indices  ||| S:1389 E:1397 ||| JJ
varied  ||| S:1397 E:1404 ||| NN
among  ||| S:1404 E:1410 ||| IN
different  ||| S:1410 E:1420 ||| JJ
hospital  ||| S:1420 E:1429 ||| NN
departments ||| S:1429 E:1440 ||| NNS
.  ||| S:1440 E:1442 ||| .
More  ||| S:1442 E:1447 ||| JJR
efforts  ||| S:1447 E:1455 ||| NNS
are  ||| S:1455 E:1459 ||| VBP
needed  ||| S:1459 E:1466 ||| VBN
toward  ||| S:1466 E:1473 ||| IN
small  ||| S:1473 E:1479 ||| JJ
hospitals ||| S:1479 E:1488 ||| NNS
,  ||| S:1488 E:1490 ||| ,
prophylactic  ||| S:1490 E:1503 ||| JJ
antimicrobial  ||| S:1503 E:1517 ||| JJ
use  ||| S:1517 E:1521 ||| NN
for  ||| S:1521 E:1525 ||| IN
surgical  ||| S:1525 E:1534 ||| JJ
patients ||| S:1534 E:1542 ||| NNS
,  ||| S:1542 E:1544 ||| ,
and  ||| S:1544 E:1548 ||| CC
departments  ||| S:1548 E:1560 ||| NNS
with  ||| S:1560 E:1565 ||| IN
low  ||| S:1565 E:1569 ||| JJ
BCRs  ||| S:1569 E:1574 ||| JJ
to  ||| S:1574 E:1577 ||| TO
optimize  ||| S:1577 E:1586 ||| VB
the  ||| S:1586 E:1590 ||| DT
clinical  ||| S:1590 E:1599 ||| JJ
antimicrobial  ||| S:1599 E:1613 ||| JJ
use ||| S:1613 E:1616 ||| NN
.  ||| S:1616 E:1618 ||| .
